DrugAnalyst Database
DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500
Log In
This site is best viewed with JavaScript enabled
Company
Sector
Drugs
Valuation
Share Prices
Portfolio
Get Access
European Pharma
Argenx
AstraZeneca
Bayer
Galapagos
Genmab
Glaxo
Grifols
GW Pharma
Ipsen
Lundbeck
Merck KGaA
Novartis
Novo Nordisk
Roche
Sanofi
UCB
US Pharma
AbbVie
Alexion
Alkermes
Alnylam
Amgen
Biogen
BioMarin
Bristol
Clovis
Endo
Gilead
Incyte
Ionis
Jazz
JnJ
Lilly
Merck
Mylan
Neurocrine
Pfizer
Regeneron
Sage
Seattle
Teva
Vertex
Asia Pacific Pharma
Astellas
Chugai
CSL
Daiichi
Eisai
Ono
Otsuka
Shionogi
Takeda
close
Peer Comparison
Total Revenue
Pharma Sales
Gross Margin
SG&A Margin
R&D Margin
Trading Margin
Tax Rate
Net Income
Incremental Margin
Net Cash/Debt to Equity Ratios
Per Employee Metrics
Growth - CAGRs
Drug Sales Expectation Change
Core Adjustments
Net Debt / EBITDA Ratios
Dividend Yield
Sector P&L
EU Major
US Major
Japanese
US Big Biotech
Price Performance
Sector Performance Charts
R&D
R&D Pipeline
close
Drugs
Biggest Drugs
Biggest Pipeline Drugs
Growers
Decliners
Upgrades
Downgrades
High/Low Analysis
Drug List
US Exposure
Therapeutic Areas
Acid Disorders
ADHD
Alzheimer's
Asthma / COPD
Atopic Dermatitis
Breast Cancer
Colorectal Cancer
Chronic Dry Eye
Cystic Fibrosis
Depression
Dyslipidaemia
Haemophilia
Diabetes: All
HCV
HIV
Hypertension
Influenza
Lung Cancer
Lymphoma (NHL/CLL)
Melanoma
Migraine
Multiple Myeloma
Multiple Sclerosis
Opthalmic (AMD / RVO / DME)
Osteoporosis
Prostate Cancer
Psoriasis
Rheumatoid Arthritis
Schizophrenia
Thrombosis
Mechanisms
Anti-PD(L)-1
Anti-PCSK-9
Anti-CD20
Anti-HER2
Anti-TNF
Anti-VEGF
Beta-amyloid
Insulin Analogues
DPP-4
GLP-1
SGLT2
JAK Inhibitors
PARP
Xa Inhibitors
Biosimilars
Avastin
Enbrel
Herceptin
Humira
Mabthera
Remicade
close
Valuation Summary
Summary Sheet
close
Valuation Metrics
P/E
P/S
PEG
Other
US Flu Tracker
Consensus Target Prices
Account
Change Password
Client Data
Show my Client Rank
Custom Models
close
Your Client Rank:
Loading...
99
Updated 06-Apr-2020
Summary
Annual Drugs
Quarterly Drugs
Annual P&L
Quarterly P&L
Changes
Growth
R&D
Drug Charts
T&Ds
FG
Results